| Literature DB >> 31121984 |
Wenjun Jiang1, Li Ren2, Mengyue Guo3, Nitin Mantri4, Sha Zhao5, Xiaohui Pang6.
Abstract
Schisandrae Chinensis Fructus (Wuweizi) is often adulterated with Schisandrae Sphenantherae Fructus (Nanwuweizi) in the herbal market. This adulteration is a threat to clinical treatment and safety. In this study, we aimed to develop a nucleotide signature for the identification of Wuweizi and its Chinese patent medicines based on the mini-DNA barcoding technique. We collected 49 samples to obtain internal transcribed spacer 2 (ITS2) sequences and developed a 26-bp nucleotide signature (5'-CGCTTTGCGACGCTCCCCTCCCTCCC-3') on the basis of a single nucleotide polymorphism (SNP) site within the ITS2 region that is unique to Wuweizi. Then, using the nucleotide signature, we investigated 27 batches of commercial crude drug samples labeled as Wuweizi and eight batches of Chinese patent medicines containing Wuweizi. Results showed that eight commercial crude drug samples were adulterants and one of the Chinese patent medicines contained adulterants. The nucleotide signature can serve as an effective tool for identifying Wuweizi and its Chinese patent medicines and can thus be used to ensure clinical drug safety.Entities:
Keywords: Chinese patent medicines; Wuweizi; identification; nucleotide signature
Mesh:
Substances:
Year: 2019 PMID: 31121984 PMCID: PMC6562420 DOI: 10.3390/genes10050397
Source DB: PubMed Journal: Genes (Basel) ISSN: 2073-4425 Impact factor: 4.096
Figure 1Samples of Schisandrae Chinensis Fructus and Schisandrae Sphenantherae Fructus collected from herbal market.
Characteristics and identification results of commercial crude drug samples labeled as Schisandrae Chinensis Fructus.
| Voucher No. | Collection Location | Genuine |
|---|---|---|
| DL01 | Dalian, Liaoning | Yes |
| DL02 | Dalian, Liaoning | Yes |
| BJ01 | Beijing | No |
| BJ02 | Beijing | Yes |
| XA01 | Xian, Shanxi | Yes |
| XA02 | Xian, Shanxi | Yes |
| WN01 | Weinan, Shanxi | No |
| NJ01 | Nanjing, Jiangsu | No |
| CZ01 | Changzhi, Shanxi | Yes |
| CZ02 | Changzhi, Shanxi | No |
| CZ03 | Changzhi, Shanxi | Yes |
| CZ04 | Changzhi, Shanxi | No |
| CZ05 | Changzhi, Shanxi | No |
| CZ06 | Changzhi, Shanxi | No |
| CZ07 | Changzhi, Shanxi | No |
| OL01 | online store | Yes |
| OL02 | online store | Yes |
| CD01 | Chengdu, Sichuan | Yes |
| CD02 | Chengdu, Sichuan | Yes |
| BZ01 | Bozhou, Anhui | Yes |
| BZ02 | Bozhou, Anhui | Yes |
| BZ03 | Bozhou, Anhui | Yes |
| BZ04 | Bozhou, Anhui | Yes |
| AG01 | Anguo, Hebei | Yes |
| TH01 | Tonghua, Jilin | Yes |
| TH02 | Tonghua, Jilin | Yes |
| LC01 | Lincun, Jilin | Yes |
Characteristics of eight Chinese patent medicines.
| Voucher | Samples | Listed Ingredients on Label | Collection Location | Genuine |
|---|---|---|---|---|
| TW01 | Tianwang Buxin Pills | Beijing store | Yes | |
| TW02 | Tianwang Buxin Pills | online shop | Yes | |
| MW01 | Maiwei Dihuang Pills | Beijing store | Yes | |
| MW02 | Maiwei Dihuang Pills | online shop | Yes | |
| ZG | Zengguang Tablets | online shop | No | |
| BT | Bantu Pills | online shop | Yes | |
| SH | Shihu Yeguang Pills | online shop | Yes | |
| AS | Anshen Capsules | online shop | Yes |
Figure 2Schematic diagram showing the location of primer pairs (ITS2F/WWZ5R, ITS2F/ITS3R) and the nucleotide signature region of S. chinensis.
Figure 3Alignment of the 26-bp nucleotide conserved region.
BLAST analysis of the 26-bp unique region.
| Source Species of Nucleotide Signature | Blast Result | Number of the Species | Max Score | Total Score | Query Cover | E Value | Per. |
|---|---|---|---|---|---|---|---|
|
|
| 39 | 52.0 | 52.0 | 100% | 0.0003 | 100% |
|
| 1 | 44.1 | 44.1 | 100% | 0.065 | 96.15% | |
|
| 1 | 44.1 | 44.1 | 100% | 0.065 | 96.15% | |
|
| 13 | 44.1 | 44.1 | 100% | 0.065 | 96.15% | |
|
| 2 | 44.1 | 44.1 | 100% | 0.065 | 96.15% | |
|
| 2 | 44.1 | 44.1 | 100% | 0.065 | 96.15% | |
|
| 4 | 44.1 | 44.1 | 100% | 0.065 | 96.15% | |
|
| 2 | 44.1 | 44.1 | 100% | 0.065 | 96.15% | |
|
| 3 | 44.1 | 44.1 | 100% | 0.065 | 96.15% | |
|
| 27 | 44.1 | 44.1 | 100% | 0.065 | 96.15% | |
|
| 6 | 44.1 | 44.1 | 100% | 0.065 | 96.15% |
Figure 4Single nucleotide polymorphisms (SNP) peaks of four batches of Chinese patent medicine containing Wuweizi.